Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Opinion
Video

Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.

Video content above is prompted by the following:

  • As treatments with greater durability emerge, how might they change your approach to treating neovascular age-related macular degeneration or diabetic macular edema? What impact will this have on treatment and monitoring schedules?
  • How will this impact workflows and clinic capacity?

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.